TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing…
WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated…
VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in…
Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacyBASKING…
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the…
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will…
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will…
ORANGE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled…
RoxyBond is the first and only immediate-release opioid medication with FDA-approved labeling describing abuse-deterrent properties.1 PRINCETON, N.J., July 06, 2022…